Have a feature idea you'd love to see implemented?
Let us know!
MLYS Mineralys Therapeutics Inc
Price (delayed)
$11.87
Market cap
$590.75M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.29
Enterprise value
$493.48M
We are a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Our product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone
Highlights
The net income has dropped by 171% year-on-year and by 28% since the previous quarter
The company's quick ratio has shrunk by 55% YoY and by 23% QoQ
Key stats
What are the main financial stats of MLYS
Market
Valuations
Earnings
Shares outstanding
49.77M
Market cap
$590.75M
Enterprise value
$493.48M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.49
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$153.25M
EBITDA
-$153.23M
Free cash flow
-$128.55M
Per share
Balance sheet
Liquidity
EPS
-$3.29
Free cash flow per share
-$2.58
Book value per share
$4.76
Revenue per share
$0
TBVPS
$5.38
Total assets
$268.25M
Total liabilities
$31.32M
Debt
$0
Equity
$236.93M
Working capital
$236.41M
Debt to equity
0
Current ratio
8.55
Quick ratio
8.42
Net debt/EBITDA
0.63
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-51.7%
Return on equity
-55.9%
Return on invested capital
-77.5%
Return on capital employed
-64.7%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MLYS stock price
How has the Mineralys Therapeutics stock price performed over time
Intraday
-5.79%
1 week
-2.47%
1 month
-14.17%
1 year
97.18%
YTD
38.02%
QTD
-1.98%
Financial performance
How have Mineralys Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$168.35M
Net income
-$153.25M
Gross margin
N/A
Net margin
N/A
The net income has dropped by 171% year-on-year and by 28% since the previous quarter
The company's operating income has shrunk by 151% YoY and by 25% QoQ
Growth
What is Mineralys Therapeutics's growth rate over time
Valuation
What is Mineralys Therapeutics stock price valuation
P/E
N/A
P/B
2.49
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has declined by 21% since the previous quarter and by 4.8% year-on-year
The stock's P/B is 25% more than its last 4 quarters average of 2.0
MLYS's equity is down by 18% since the previous quarter and by 10% year-on-year
Efficiency
How efficient is Mineralys Therapeutics business performance
The ROA has dropped by 126% year-on-year and by 29% since the previous quarter
MLYS's ROE has shrunk by 95% YoY and by 31% QoQ
MLYS's ROIC has plunged by 84% YoY and by 34% from the previous quarter
Dividends
What is MLYS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MLYS.
Financial health
How did Mineralys Therapeutics financials performed over time
MLYS's total liabilities has soared by 131% YoY and by 10% from the previous quarter
The current ratio has plunged by 56% YoY and by 24% from the previous quarter
Mineralys Therapeutics's debt is 100% lower than its equity
MLYS's equity is down by 18% since the previous quarter and by 10% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.